2021
Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose
Krantz MS, Kwah JH, Stone CA, Phillips EJ, Ortega G, Banerji A, Blumenthal KG. Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose. JAMA Internal Medicine 2021, 181: 1530-1533. PMID: 34309623, PMCID: PMC8314170, DOI: 10.1001/jamainternmed.2021.3779.Peer-Reviewed Original ResearchCytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19
Azmy V, Kaman K, Tang D, Zhao H, Dela Cruz C, Topal JE, Malinis M, Price CC. Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19. Journal Of Clinical Immunology 2021, 41: 738-747. PMID: 33459964, PMCID: PMC7812117, DOI: 10.1007/s10875-020-00949-6.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedBiomarkersCOVID-19COVID-19 Drug TreatmentCytokine Release SyndromeCytokinesDrug Therapy, CombinationFeasibility StudiesFemaleGlucocorticoidsHospitalizationHumansImmunologic FactorsMaleMiddle AgedRetrospective StudiesSARS-CoV-2Severity of Illness IndexTreatment OutcomeYoung AdultConceptsIL-10 levelsIL-6IL-10Disease severityCytokine profileD-dimerTreatment algorithmCritical SARS-CoV-2 infectionCOVID-19SARS-CoV-2 infectionAdministration of tocilizumabAdmission IL-6Maximum oxygen requirementsTocilizumab-treated patientsElevated IL-6Immune-modulating therapyCritical COVID-19Retrospective chart reviewTertiary care centerIL-6 levelsMean IL-6IL-6 inhibitionAdministration of glucocorticoidsRole of cytokinesCytokine elevation
2020
Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes
Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes. CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.Peer-Reviewed Original ResearchConceptsCytokine release syndromeTocilizumab-treated patientsSevere diseaseRelease syndromeTocilizumab treatmentInflammatory biomarkersNonsevere diseaseSoluble IL-2 receptor levelsHigh-sensitivity C-reactive proteinIL-2 receptor levelsConsecutive COVID-19 patientsIL-6 receptor antagonistMechanical ventilation outcomesC-reactive proteinCOVID-19 patientsHigher admission levelsRace/ethnicityMV daysVentilation outcomesAdverse eventsChart reviewClinical responseMedian ageWhite patientsClinical outcomes
2018
Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects
Schwab C, Gabrysch A, Olbrich P, Patiño V, Warnatz K, Wolff D, Hoshino A, Kobayashi M, Imai K, Takagi M, Dybedal I, Haddock JA, Sansom DM, Lucena JM, Seidl M, Schmitt-Graeff A, Reiser V, Emmerich F, Frede N, Bulashevska A, Salzer U, Schubert D, Hayakawa S, Okada S, Kanariou M, Kucuk ZY, Chapdelaine H, Petruzelkova L, Sumnik Z, Sediva A, Slatter M, Arkwright PD, Cant A, Lorenz HM, Giese T, Lougaris V, Plebani A, Price C, Sullivan KE, Moutschen M, Litzman J, Freiberger T, van de Veerdonk FL, Recher M, Albert MH, Hauck F, Seneviratne S, Pachlopnik Schmid J, Kolios A, Unglik G, Klemann C, Speckmann C, Ehl S, Leichtner A, Blumberg R, Franke A, Snapper S, Zeissig S, Cunningham-Rundles C, Giulino-Roth L, Elemento O, Dückers G, Niehues T, Fronkova E, Kanderová V, Platt CD, Chou J, Chatila TA, Geha R, McDermott E, Bunn S, Kurzai M, Schulz A, Alsina L, Casals F, Deyà-Martinez A, Hambleton S, Kanegane H, Taskén K, Neth O, Grimbacher B. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects. Journal Of Allergy And Clinical Immunology 2018, 142: 1932-1946. PMID: 29729943, PMCID: PMC6215742, DOI: 10.1016/j.jaci.2018.02.055.Peer-Reviewed Original ResearchConceptsMutation carriersClinical featuresTreatment optionsCTLA4 mutationsCytotoxic T-lymphocyte antigen-4Complex immune dysregulation syndromeNatural killer cell countsT-lymphocyte antigen-4Hematopoietic stem cell transplantationAffected mutation carriersCTLA-4 fusion proteinCTLA-4 insufficiencyMain clinical manifestationsStem cell transplantationBest treatment optionNegative immune regulatorT lymphocyte antigenImmune dysregulation syndromeYears of ageAutoimmune cytopeniasEBV associationEBV reactivationMedian ageClinical manifestationsRapamycin inhibitors
2015
Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab—for how long?
Barmettler S, Price C. Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab—for how long? Journal Of Allergy And Clinical Immunology 2015, 136: 1407-1409. PMID: 26277594, DOI: 10.1016/j.jaci.2015.06.035.Peer-Reviewed Original Research